GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Debt-to-EBITDA

BOLD (Boundless Bio) Debt-to-EBITDA : -0.01 (As of Jun. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Boundless Bio Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Boundless Bio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.84 Mil. Boundless Bio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Boundless Bio's annualized EBITDA for the quarter that ended in Jun. 2024 was $-76.50 Mil. Boundless Bio's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was -0.01.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Boundless Bio's Debt-to-EBITDA or its related term are showing as below:

BOLD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.11   Med: -0.04   Max: -0.01
Current: -0.01

During the past 3 years, the highest Debt-to-EBITDA Ratio of Boundless Bio was -0.01. The lowest was -0.11. And the median was -0.04.

BOLD's Debt-to-EBITDA is ranked worse than
100% of 269 companies
in the Biotechnology industry
Industry Median: 1.5 vs BOLD: -0.01

Boundless Bio Debt-to-EBITDA Historical Data

The historical data trend for Boundless Bio's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boundless Bio Debt-to-EBITDA Chart

Boundless Bio Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
-0.02 -0.11 -0.04

Boundless Bio Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.10 -0.07 -0.04 -0.02 -0.01

Competitive Comparison of Boundless Bio's Debt-to-EBITDA

For the Biotechnology subindustry, Boundless Bio's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boundless Bio's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Boundless Bio's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Boundless Bio's Debt-to-EBITDA falls into.


Boundless Bio Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Boundless Bio's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(2.195 + 0) / -53.839
=-0.04

Boundless Bio's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.837 + 0) / -76.504
=-0.01

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Jun. 2024) EBITDA data.

Boundless Bio  (NAS:BOLD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Boundless Bio Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Boundless Bio's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.

Boundless Bio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Boundless Bio Inc (NAS:BOLD) » Definitions » Debt-to-EBITDA
Comparable Companies
Traded in Other Exchanges
N/A
Address
9880 Campus Point Drive, Suite 120, San Diego, CA, USA, 92121
Website
https://www.boundlessbio.com
Boundless Bio Inc is a clinical-stage oncology company. It is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the significant unmet need in patients with oncogene amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in more than 14% of cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.